Bibliography
- PSATY BM, FURBERG CD: COX-2 inhibitors - lessons in drug safety. N Engl. J. Med. (2005) 352(11):1133–1135.
- CHENG Y, AUSTIN SC, ROCCA B et al.: Role of prostacyclin in the cardiovascular response to thromboxane A2. Science (2002) 296(5567):539–541.
- • An important article demonstrating that COX-2 inhibition could increase the risk of thromboembolic events.
- CATELLA-LAWSON F, MCADAM B et al.: Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharm. Exp. Ther. (1999) 289 (2):735–741.
- AW T-J, HAAS SJ, LIEW DL: Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch. Intern. Med. (2005) 165(5):490–496.
- MOH JH, CHOI YH et al.: A prodrug approach to COX-2 inhibitors with methylsulfone. Bioorg-. Med. Chem. Lett. (2004) 14(7):1757–1760.
- • An article on the use of methylsulfoxide derivatives as prodrugs for methylsulfone COX-2 inhibitors.
- CATURLA F, JIMENEZ J-M et al.: Synthesis and biological evaluation of 2-phenylpyran-4-ones: A new class of orally active cyclooxygenase-2 inhibitors. J. Med. Chem. (2004) 47(15):3874–3886.
- RIENDEAU D, PERCIVAL MD, BRIDEAU C et al.: Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. j Pharm. Exp. Ther. (2001) 296(2):558–566.
- ROLF C, ENGSTROM B et al.: Intra-articular absorption and distribution of ketoprofen after topical plaster application and oral intake in 100 patients undergoing knee arthroscopy. Rheumatology (1999) 38(6):564–567.
- DEGNER F, SIGMUND R, ZEIDLER H: Efficacy and tolerability of meloxicam in an observational, controlled cohort study in patients with rheumatic disease. Clin. Then (2000) 22(4):400–410.
- CHUNG S, LIM KM, SHIN SS: Profiles of COX-2 inhibitors: present and future. Expert Opin. Ther. Patents (2005) 15(1):9–32.